MAGEA9 and cancer: Bergeron et al. (2009) showed that MAGEA4 and MAGEA9 were expressed in 38% and 63% of NMIBC, in 48% and 57% of MIBC, 65% and 84% in carcinomas in situ, and 73% and 85% in lymph node metastases, respectively.